Nonrelapse mortality and relapse incidence stratified by risk factors. Competing risk analysis for NRM and RI stratified by (A) pre-alloHCT cytogenetic response, (B) inclusion of melphalan in conditioning regimen, (C) PTCy for GVHD prophylaxis, and (D) presence of only non-DBD TP53^mut.